We are Bilthoven Biologicals
For Public Health. Since 1909For over a century, we have been accelerating access to vaccines
We believe in a world where protection is not a privilege, but a given. Together with our parent company, Serum Institute of India, we are committed to delivering biologicals against infectious diseases worldwide. Our expertise also supports partners in developing new vaccines, helping to increase global accessibility. Because health is a human right – and protection works best when it’s shared.
For over a century, we have been accelerating access to vaccines
We believe in a world where protection is not a privilege, but a given. Together with our parent company, Serum Institute of India, we are committed to delivering biologicals against infectious diseases worldwide. Our expertise also supports partners in developing new vaccines, helping to increase global accessibility. Because health is a human right – and protection works best when it’s shared.
countries served
lives impacted
Comprehensive vaccine portfolio protecting against infectious diseases worldwide.
Working together with leading organizations to improve global health
Working together with leading organizations to improve global health




Through strategic partnerships
we accelerate accessibility
of vaccines.
Stay updated with our latest developments and achievements
See all news
Report on Bilthoven Biologicals Pandemic Preparedness Facility in Dutch newspaper NRC

Bilthoven Biologicals, a Cyrus Poonawalla Group company, opens Pandemic Preparedness Vaccine Facilities

European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe

Report on Bilthoven Biologicals Pandemic Preparedness Facility in Dutch newspaper NRC

Bilthoven Biologicals, a Cyrus Poonawalla Group company, opens Pandemic Preparedness Vaccine Facilities

European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe
Stay updated with our latest developments and achievements
See all news
Report on Bilthoven Biologicals Pandemic Preparedness Facility in Dutch newspaper NRC

Bilthoven Biologicals, a Cyrus Poonawalla Group company, opens Pandemic Preparedness Vaccine Facilities

European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe

Report on Bilthoven Biologicals Pandemic Preparedness Facility in Dutch newspaper NRC

Bilthoven Biologicals, a Cyrus Poonawalla Group company, opens Pandemic Preparedness Vaccine Facilities

European Commission Grants Marketing Authorisation for SIILTIBCY® – A Novel Tuberculosis Skin Test in Europe
Join our mission!
We believe in a world where protection is not a privilege, but a given. Are you interested in helping us achieve that goal?

